About belimumab
B-lymphocyte stimulator inhibitor
Used for
- Treats active systemic lupus erythematosus with standard therapy
- Treats active lupus nephritis with standard therapy
Usual adult dose
Intravenous: 10 mg/kg at weeks 0, 2, and 4, then every 4 weeks. For lupus nephritis, also use with standard treatment.
Usual dose in children
For children aged 5 years and older with lupus: intravenous 10 mg/kg at weeks 0, 2, and 4, then every 4 weeks.
Common side effects
- Nausea, diarrhoea, or fever
- Infusion or injection reactions
- Infections
- Depression or suicidal thoughts
Important warnings
- Serious infections can occur; treatment may need to be paused.
- Seek urgent care for severe allergic reactions during or after infusion.
- Mood changes and suicidal thoughts have been reported.
- Live vaccines should generally be avoided during treatment.
Pregnancy
May harm an unborn baby; discuss pregnancy plans with a healthcare professional. Pregnancy registry information is available.
Breastfeeding
It is unknown whether belimumab passes into breast milk; discuss benefits and potential risks with a healthcare professional.
Interactions
- Other biologic medicines that suppress the immune system may increase infection risk.
- Cyclophosphamide and other immunosuppressants may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.